Does fXR activation improve myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity?
FXR agonism exerts beneficial effects in a genetic model of lipid-induced cardiomyopathy. The striking benefit of this therapy on cardiac function in this model warrants an effort to determine whether a counterpart of this activity translates in human settings.
Reasonable response rates for biological sample collection should be expected in future case controls studies in younger women, but other methods of control selection must be devised.